APR-246 يعزز التأثير المضاد للسرطان لعقار الدوكسوروبيسين ضد خلايا سرطان البنكرياس AsPC-1 المتحولة p53

Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019; 10(1): 10. https://doi.org/10.14740/wjon1166

Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37: 1-13.https://doi.org/10.1186/s13046-018-0705-7

Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020; 13(1): 1-20.https://doi.org/10.1186/s13045-020-00958-3

Du J, Gong H, Xiao H. Somatic TP53 mutations and comparison of different TP53 functional domains in human cancers: Data analysis from the IARC TP53 database and the National Cancer Institute GDC data portal. Med Data Min. 2021; 4(3): 1-10.https://doi.org/10.12032/MDM2021033003

Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022; 29(5): 946-60.https://doi.org/10.1038/s41418-022-00988-z

Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review. Molecules (Basel, Switzerland). 2022; 27(14): 4478.https://doi.org/10.3390/molecules27144478

Mohammed I, Alhammer AH, Arif IS. The p53 reactivator PRIMA-1(MET) synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells. Invest New Drugs. 2023; 41(4): 587-95.https://doi.org/10.1007/s10637-023-01380-5

Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021; 39(14): 1584-94.https://doi.org/10.1200/jco.20.02341

Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F, et al. Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still A Mutant P53-Dependent Affair?. Cells. 2021; 10(1): 98.https://doi.org/10.3390/cells10010098

Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023; 10(4): e272-e83.https://doi.org/10.1016/S2352-3026(22)00403-3

Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investig New Drugs. 2014; 32: 783-94.https://doi.org/10.1007/s10637-014-0090-9.

Ali SM, Al-Karam LQ, Alhammer AJN. In Vitro Cancer Cells Therapy with Nano-gold Depending on its Optical Properties. Neuroquantology 2022; 20(2): 57.https://doi.org/10.14704/nq.2022.20.2.NQ22025

Alfardan RJBSJ. Small Nuclear RNA 64 (snoRNA64): A novel Tumor Biomarker for Pancreatic Cancer. Baghdad Sci J. 2023; 20((5Suppl.)): 1873-81.https://doi.org/10.21123/bsj.2023.7135

Nashaan FA, Al-Rawi MS, Alhammer AH, Rabie AM, Tomma JH. Synthesis, characterization, and cytotoxic activity of some imides from galloyl hydrazide. Eurasian Chem Commun. 2022; 4(10): 966-75.https://doi.org/10.22034/ecc.2022.340135.1453

Al-Juboori SKE, Al-Juboori SIK. Hepatocellular Carcinoma Prediction and early Diagnosis of Hepatitis B and C viral infection using miR-122 and miR-223 in a sample of Iraqi patients. Baghdad Sci J. 2023; 20(4(SI)): 1520.https://doi.org/10.21123/bsj.2023.9065

Ploner C, Kofler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene. 2008; 27 Suppl 1(Suppl 1): S84-92.https://doi.org/10.1038/onc.2009.46

Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1): 31-46.https://doi.org/10.1158/2159-8290.cd-21-1059

Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg. 2021; 25(3): 315-27.https://doi.org/10.14701/ahbps.2021.25.3.315

Guo Y, Tang Y, Lu G, Gu J. p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act. Nutrients. 2023; 15(10): 2259-82.https://doi.org/10.3390/nu15102259

Bykov VJ, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018; 18(2): 89-102.https://doi.org/10.1038/nrc.2017.109.

Yoshikawa N, Kajiyama H, Nakamura K, Utsumi F, Niimi K, Mitsui H, et al. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells. Oncol Rep. 2016; 35(5): 2543-52.https://doi.org/10.3892/or.2016.4653

Liu J, Huang Y, Liu Y, Chen Y. Irisin enhances doxorubicin-induced cell apoptosis in pancreatic cancer by inhibiting the PI3K/AKT/NF-κB pathway. Med Sci Monit. 2019; 25: 6085.https://doi.org/10.12659/MSM.917625

Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and NoxaAntimyeloma Activity of PRIMA-1Met. Mol Cancer Ther. 2013; 12(11): 2331-41.https://doi.org/10.1158/1535-7163.MCT-12-1166.

Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015; 6(6): e1794.https://doi.org/10.1038/cddis.2015.143

Müller M, Rösch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, et al. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers. 2021; 13(17): 4476-99.https://doi.org/10.3390/cancers13174476

Basu B, Gourley C, Gabra H, Vergote IB, Brenton JD, Abrahmsen L, et al. PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC). Ann Oncol. 2016; 27: vi123.https://doi.org/10.1093/annonc/mdw368.29

Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016; 6: 21.https://doi.org/10.3389/fonc.2016.00021.

Basile KJ, Aplin AE. Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res. 2012; 2(6): 726-35

Lu T, Zou Y, Xu G, Potter JA, Taylor GL, Duan Q, et al. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK. Oncotarget. 2016; 7(50): 83017.https://doi.org/10.18632/oncotarget.12940

Yang MC, Lin RW, Huang SB, Huang SY, Chen WJ, Wang S, et al. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. Cell Cycle. 2016; 15(3): 394-402.https://doi.org/10.1080/15384101.2015.1127470

Almohaidi AMS, Hassan FM, Rothan H. Editorial: Current advances in anti-infective strategies. Baghdad Sci. J. 2023;20(5):1570. https://doi.org/10.21123/bsj.2023.9731